肺腺癌中 lncRNAs 相关免疫基因特征的综合分析及其与免疫治疗的相关性。
Comprehensive analysis of the lncRNAs-related immune gene signatures and their correlation with immunotherapy in lung adenocarcinoma.
机构信息
Joint National Laboratory for Antibody Drug Engineering, the First Affiliated Hospital, School of Basic Medical Sciences, Henan University, Kaifeng, China.
Department of Immunology, School of Basic Medical Sciences, Henan University, Kaifeng, China.
出版信息
Br J Cancer. 2023 Oct;129(9):1397-1408. doi: 10.1038/s41416-023-02379-8. Epub 2023 Aug 5.
BACKGROUND
Long non-coding RNAs (lncRNAs)-related immune genes (lrRIGs) play a crucial role in the development and progression of lung adenocarcinoma (LUAD). However, reliable prognostic signatures based on lrRIGs have not yet been identified.
METHODS
We screened lrRIGs associated with the prognosis of LUAD using The Cancer Genome Atlas (TCGA) database and then established a novel prognostic nine-gene signature composed of CD79A, INHA, SHC3, LIFR, TNFRSF11A, GPI, F2RL1, SEMA7A and WFDC2 through bioinformatic approaches. A risk score derived from this gene signature was used to divide LUAD patients into the low- and high-risk groups. The latter was confirmed to have markedly worse overall survival (O.S.). A nomogram was developed using the risk score and other independent prognostic elements, demonstrating excellent performance in predicting the O.S. rate of LUAD patients.
RESULTS
We observed that the infiltration of diverse immune cell subtypes and response to immunotherapy and chemotherapy significantly differed between the low- and high-risk groups.
CONCLUSIONS
Overall, stratification based on this gene signature could be used to guide better therapeutic management and improve outcomes for LUAD patients.
背景
长非编码 RNA（lncRNA）相关免疫基因（lrRIGs）在肺腺癌（LUAD）的发生和发展中起着至关重要的作用。然而，基于 lrRIGs 的可靠预后标志物尚未被确定。
方法
我们使用癌症基因组图谱（TCGA）数据库筛选与 LUAD 预后相关的 lrRIGs，然后通过生物信息学方法建立了由 CD79A、INHA、SHC3、LIFR、TNFRSF11A、GPI、F2RL1、SEMA7A 和 WFDC2 组成的新型预后九基因特征。基于该基因特征的风险评分用于将 LUAD 患者分为低风险组和高风险组。后者的总生存期（O.S.）明显较差。使用风险评分和其他独立预后因素开发了列线图，在预测 LUAD 患者 O.S.率方面表现出优异的性能。
结果
我们观察到，低风险组和高风险组之间不同免疫细胞亚型的浸润以及对免疫治疗和化疗的反应有显著差异。
结论
总的来说，基于该基因特征的分层可以用于指导 LUAD 患者的更好治疗管理并改善其预后。
Zotero 插件